Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 3/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.32 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.32 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30759521 | 0.90 | SLC1A2 (0.35) | SLC1A2SLC1A1SLC1A3DPP7GRIK1 | |
| SCHEMBL30759400 | 0.81 | SLC7A5 (0.40) | — | |
| SCHEMBL30759453 | 0.75 | SLC7A5 (0.42) | CA1CA2 | |
| SCHEMBL30759342 | 0.73 | DPP7 (0.46) | SLC1A2SLC1A1SLC1A3DPP7DPP4 | |
| SCHEMBL31754346 | 0.73 | SLC1A2 (0.39) | SLC1A2SLC1A1SLC1A3DPP7DPP4 | |
| SCHEMBL16710358 | 0.65 | ALDH1A1 (0.50) | SLC1A2SLC1A1SLC1A3DPP7DPP4 | |
| SCHEMBL6445484 | 0.64 | DPP7 (0.50) | SLC1A2SLC1A1SLC1A3DPP7DPP4 | |
| SCHEMBL21114423 | 0.64 | DPP7 (0.50) | SLC1A2SLC1A1SLC1A3DPP7DPP4 | |
| SCHEMBL5497695 | 0.64 | DPP7 (0.50) | SLC1A2SLC1A1SLC1A3DPP7DPP4 | |
| SCHEMBL2785915 | 0.64 | DPP7 (0.50) | SLC1A2SLC1A1SLC1A3DPP7DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4558513-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | Merck Sharp & Dohme LLC (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024020159-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2024-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | SLC1A2 4093/4885SLC1A1 2783/4885SLC1A3 2477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.